P&G sales hit by PGT termination
This article was originally published in OTC Bulletin
Executive Summary
Innovation, marketing investments and price increases helped Procter & Gamble’s (P&G’s) Personal Health Care sales grow at a “double digit” rate on an organic basis in its first quarter ended 30 September 2018.
You may also be interested in...
P&G Raises Forecast On Strong First Half, Notes Price Increases As Potential Drag
P&G reports 4% organic growth in its fiscal 2019 Q2, building on a strong Q1 and prompting it to raise full-year organic guidance 1%. CFO Jon Moeller warns, however, possible market volatility and competitor activity related to potential price increases could sink its positive estimate.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.